Jagat R Kanwar, Kanwar R. Jagat, Rakesh Jagat, Rakesh J, JR Kanwar
Jagat R Kanwar, Kanwar R. Jagat, Rakesh Jagat, Rakesh J, JR Kanwar
All India Institute of Medical Sciences (AIIMS), Bhopal, INDIA, MP.
Verified email at
Cited by
Cited by
Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives
D Chen, M Frezza, S Schmitt, J Kanwar, Q P Dou
Current cancer drug targets 11 (3), 239-253, 2011
Gene transfer of antisense hypoxia inducible factor-1 α enhances the therapeutic efficacy of cancer immunotherapy
X Sun, JR Kanwar, E Leung, K Lehnert, D Wang, GW Krissansen
Gene therapy 8 (8), 638-645, 2001
Recent advances on the roles of NO in cancer and chronic inflammatory disorders
JR Kanwar, RK Kanwar, H Burrow, S Baratchi
Current medicinal chemistry 16 (19), 2373-2394, 2009
Progress on Azadirachta indica based biopesticides in replacing synthetic toxic pesticides
S Chaudhary, RK Kanwar, A Sehgal, DM Cahill, CJ Barrow, R Sehgal, ...
Frontiers in Plant Science 8, 610, 2017
Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy
JR Kanwar, WP Shen, RK Kanwar, RW Berg, GW Krissansen
Journal of the National Cancer Institute 93 (20), 1541-1552, 2001
Treat cancers by targeting survivin: just a dream or future reality?
MS Coumar, FY Tsai, JR Kanwar, S Sarvagalla, CHA Cheung
Cancer treatment reviews 39 (7), 802-811, 2013
Mouse B7-H3 induces antitumor immunity
X Sun, M Vale, E Leung, JR Kanwar, R Gupta, GW Krissansen
Gene therapy 10 (20), 1728-1734, 2003
Chimeric aptamers in cancer cell-targeted drug delivery
JR Kanwar, K Roy, RK Kanwar
Critical reviews in biochemistry and molecular biology 46 (6), 459-477, 2011
Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6
SL Mo, YH Liu, W Duan, MQ Wei, JR Kanwar, SF Zhou
Current drug metabolism 10 (7), 730-753, 2009
Microfluidic devices for cell cultivation and proliferation
M Tehranirokh, AZ Kouzani, PS Francis, JR Kanwar
Biomicrofluidics 7 (5), 051502, 2013
Targeting survivin in cancer: the cell-signalling perspective
JR Kanwar, SK Kamalapuram, RK Kanwar
Drug discovery today 16 (11-12), 485-494, 2011
Multifunctional iron bound lactoferrin and nanomedicinal approaches to enhance its bioactive functions
JR Kanwar, K Roy, Y Patel, SF Zhou, MR Singh, D Singh, M Nasir, ...
Molecules 20 (6), 9703-9731, 2015
Nanoparticles in the treatment and diagnosis of neurological disorders: untamed dragon with fire power to heal
JR Kanwar, X Sun, V Punj, B Sriramoju, RR Mohan, SF Zhou, A Chauhan, ...
Nanomedicine: Nanotechnology, Biology and Medicine 8 (4), 399-414, 2012
Hydrogen sulfide attenuates carbon tetrachloride-induced hepatotoxicity, liver cirrhosis and portal hypertension in rats
G Tan, S Pan, J Li, X Dong, K Kang, M Zhao, X Jiang, JR Kanwar, H Qiao, ...
PloS one 6 (10), e25943, 2011
Ribosome inactivating proteins (RIPs) from Momordica charantia for anti viral therapy
M Puri, I Kaur, RK Kanwar, RC Gupta, A Chauhan, JR Kanwar
Current Molecular Medicine 9 (9), 1080-1094, 2009
Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis
JR Kanwar, RK Kanwar, GW Krissansen
Brain 127 (6), 1313-1331, 2004
Viral RNA silencing suppressors (RSS): novel strategy of viruses to ablate the host RNA interference (RNAi) defense system
S Bivalkar-Mehla, J Vakharia, R Mehla, M Abreha, JR Kanwar, A Tikoo, ...
Virus research 155 (1), 1-9, 2011
Recent advances in anti-survivin treatments for cancer
RK Kanwar, CH A Cheung, JY Chang, JR Kanwar
Current medicinal chemistry 17 (15), 1509-1515, 2010
Survivin signaling in clinical oncology: a multifaceted dragon
JR Kanwar, SK Kamalapuram, RK Kanwar
Medicinal research reviews 33 (4), 765-789, 2013
β7 integrins contribute to demyelinating disease of the central nervous system
JR Kanwar, JEB Harrison, D Wang, E Leung, W Mueller, N Wagner, ...
Journal of neuroimmunology 103 (2), 146-152, 2000
The system can't perform the operation now. Try again later.
Articles 1–20